Posted by Michael Wonder on 05 Mar 2024
Formosa Pharmaceuticals and AimMax Therapeutics receive FDA approval for clobetasol propionate 0.05% ophthalmic suspension for the treatment of post-operative inflammation and pain following ocular surgery
4 March 2024 - Formosa Pharmaceuticals and AimMax Therapeutics announced today that the US FDA has approved clobetasol propionate 0.05% ophthalmic suspension (APP13007), for the treatment of post-operative inflammation and pain following ocular surgery.
Utilising a super potent corticosteroid, clobetasol propionate ophthalmic suspension 0.05% is derived from Formosa Pharma's proprietary APNT nanoparticle formulation platform.
